iatrogenic thyrotoxicosis describes a clinical condition where excessive thyroid hormone is introduced into the body through medical intervention, rather than arising from an intrinsic glandular disorder like Graves' disease. This state typically occurs as a consequence of treatment for underlying thyroid conditions or other non-thyroidal illnesses, where the dosage of thyroid hormone or the effect of administered iodine overwhelms the body's regulatory capacity. Recognizing the distinction between endogenous hyperthyroidism and iatrogenic causes is critical for clinicians, as the management strategy diverges significantly from standard protocols for Graves' disease or toxic nodular goiter.
Mechanisms of Iatrogenesis
The pathophysiology centers on the exogenous delivery of thyroid hormone or the triggering of excessive hormone release. The most common scenario involves overtreatment with levothyroxine sodium in patients prescribed for hypothyroidism or thyroid cancer suppression, where dose escalation exceeds the body's metabolic requirements. Alternatively, iatrogenic thyrotoxicosis can manifest after diagnostic procedures involving high-dose iodine, such as contrast-enhanced imaging, particularly in individuals with latent autonomous thyroid function. A less frequent but notable mechanism is factitious thyrotoxicosis, where intentional ingestion of thyroid hormone, often by bodybuilders or individuals seeking weight loss, creates a biochemical profile indistinguishable from true hyperthyroidism.
Iatrogenic thyrotoxicosis factitia
This specific subtype arises from the surreptitious ingestion of thyroid hormone, presenting a diagnostic challenge due to the suppression of endogenous thyroid-stimulating hormone (TSH). Patients may exhibit classic signs of thyrotoxicosis, yet the radioactive iodine uptake (RAIU) scan typically reveals a suppressed gland, a key differentiator from inflammatory or Graves' causes. Diagnosis hinges on a high index of suspicion, coupled with laboratory findings showing a non-elevated thyroglobulin level and the detection of exogenous hormone in serum assays. Management focuses on cessation of the exogenous source and supportive care, as the condition resolves once the hormone is cleared from the system.
Clinical Presentation and Diagnosis
The symptomatology mirrors spontaneous thyrotoxicosis, encompassing tachycardia, palpitations, anxiety, heat intolerance, and weight loss, but the context of recent medical treatment provides a crucial diagnostic clue. A patient recovering from thyroidectomy who develops agitation and arrhythmia, or an elderly individual on cardiovascular therapy presenting with new-onset atrial fibrillation, necessitates an immediate review of their thyroid hormone regimen. Diagnosis is confirmed through a triad of laboratory values: a suppressed TSH, elevated free thyroxine (FT4), and often elevated triiodothyronine (T3) levels. Careful correlation with the clinical timeline is essential to distinguish iatrogenic causes from other etiologies.
